secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0001437749-22-006127
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology raises $10M via private placement with CEO and Athyrium
--------------------------------------------------------------------------

- Sold 3,584,228 shares at $2.79 each to CEO Alan Auerbach and an Athyrium fund for $10M gross proceeds.
- Each purchaser committed ~$5M; placement closed March 10, 2022, at closing price.
- Proceeds will be used for general corporate purposes; company to file resale registration statement within 135 days.
- Private placement exempt from registration under Section 4(a)(2) of Securities Act.
- CEO Auerbach participated alongside Athyrium, an existing noteholder affiliate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922006127/0001437749-22-006127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922006127/pbyi20220310_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-006127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer